Pituitary protein 7B2 plasma levels in patients with liver disease: Comparisons with other hormones and neuropeptides

MARIA S. VENETIKOU1, LUKE MELEAGROS2, MOHHAMMAD A. GHATEI3 and STEPHEN R. BLOOM3

1Department of Medical Sciences, Faculty of Health and Caring Professions, Technological Educational Institute (TEI), Athens, Greece; 2Department of Surgery, Middlesex Hospital; 3Department of Investigative Medicine, Imperial College, Hammersmith Hospital, London, UK

Received December 10, 2012; Accepted April 30, 2013

DOI: 10.3892/ol.2013.1384

Abstract. 7B2, a protein initially isolated from the porcine pituitary gland, has been identified in numerous animal and human tissues, with the highest concentrations in the pituitary and hypothalamus. The 7B2 molecule is highly evolutionarily conserved and is considered to be indispensable in the function and regulation of proprotein convertase 2 (PC2). In the present study, the plasma 7B2 immunoreactivity (7B2-IR) of 18 patients with liver disease was studied. Of these patients, seven (three male and four female), aged 37-67 [54.6±13.5 (SD)] years, suffered from liver cirrhosis of cryptogenic (n=2) or alcoholic (n=5) aetiology. The remaining 11 patients (four male and seven female), aged 22-76 [56.1±17.6 (SD)] years, suffered from miscellaneous liver abnormalities. The clinical diagnosis was confirmed in the majority of patients by the histological examination of a percutaneous liver biopsy or by appropriate radiological investigations. Plasma bilirubin, alkaline phosphatase, aspartate aminotransferase, albumin, prothrombin time, electrolytes, urea and creatinine were measured. The plasma 7B2-IR levels were estimated using a sensitive radiimmunoassay (RIA), and the elution position of 7B2-IR was verified by gel chromatography. The mean plasma 7B2-IR concentration in patients with liver disease was 99.44±15.9 pmol/l. In the patients with hepatocellular damage due to metastatic tumours [Ca bronchus, carcinoid (n=6)], the 7B2-IR concentrations were significantly higher [185±36.9 pmol/l, (P<0.05)] compared with the overall subjects with liver damage. The results of the present study demonstrate that 7B2-IR is increased in liver disease, with the highest levels detected in patients with tumourous liver conditions.

Introduction

The liver is central to body metabolism and when it is affected by diseases, such as cirrhosis, its complex functions are invariably impaired. Changes in the metabolism of several hormones have been observed in liver disease.

It was reported that 8 to 68% of 44 patients with hepatocellular carcinoma had increased levels of α- and β-human chorionic gonadotropin (hCG) subunits, calcitonin, parathyroid hormone (PTH), prolactin (PRL), adrenocorticotropic hormone (ACTH) and growth hormone (GH). Due to the simultaneous increases of these hormones in cirrhosis, their production is likely to be due to the metabolic effects of liver cell dysfunction rather than ectopic production (1). Corticotrophin releasing hormone (CRH) has been shown to be secreted by NPL-KC (a human hepatoma cell line) and behave as a hypothalamic CRH (2). CRH and ACTH were observed to be produced by liver and lung metastases in a patient with a pituitary carcinoma and the clinical presentation of Cushing's disease (3).

In males with liver cirrhosis, a reduction in free testosterone in the serum was shown to be associated with normal basal lutenising hormone (LH) and follicle-stimulating hormone (FSH), suggesting impaired function of the hypothalamic-pituitary-gonadal axis (4). The low testosterone level and the derangement of the hypothalamic-pituitary function have a role in the sexual dysfunction and changes in sex hormones that occur in male patients with cirrhosis (5). The LH levels of amenorrhoic females with various aetiologies of cirrhosis were shown to have decreased below the normal range in 50% of patients with alcoholic cirrhosis and 42% of patients with non-alcoholic cirrhosis, and tests revealed that the hypothalamus, rather than the pituitary, was the site of the disturbance in gonadotrophin secretion (6). Gonadotrophin-releasing hormone (GnRH) receptors have been localised in various differentiated hepatocarcinoma tissues and their expression in these tissues is associated with the degree of differentiation (7). Treatment with a combination of sex hormone suppression and inhibition of their target receptors has been attempted in the tissues of patients with hepatocellular carcinoma (8,9).

In patients with cirrhosis, the hypothalamic-pituitary-adrenal and -gonadal axes and PRL secretion are impaired. The response of GH to GH-releasing hormone (GHRH) is also accelerated, and elevated basal and stimulated levels of GH possibly reflect compensation for the low levels of IGF-1, which is associated with deteriorating liver function (8). No effects of the aetiology of cirrhosis on the degree
Serum ghrelin, tumour necrosis factor (TNF)-α and interleukin 6 (IL6) levels have been reported to be significantly higher in cirrhosis and hepatocellular carcinoma patients, whereas serum leptin levels were observed to be decreased (12). Amphiregulin (AR), a member of the epidermal growth factor family has been shown increased in liver cirrhosis and behaves as a potent pro-regenerative and survival factor (13). Neurotensin (NT) is expressed in the human fetal liver, but not in the adult; in the fibrolamellar carcinoma, (NT) is also expressed but not expressed in the regenerating rat liver (14). Somatostatin (SRIH), cortisotatin and SRIH receptor subtypes are present in rat Kupfer cells where they may function in an autocrine manner (15). SRIH analogs (SSTs) have produced promising results for the treatment of hepatocellular cancer and a long-acting SST analog (lanreotide; LAN) exhibited the ability to decrease the S-phase fraction, as well as induce apoptosis in HepG2 cells in a dose-dependent manner (16). Peptide 23, a newly identified protein by rat pituitary cells, is stimulated by GH and inhibited by SRIH. Peptide 23-cDNA has ~73% homology with human hepatocellular carcinoma cDNA from human hepatocellular carcinoma (17).

The majority of liver tumours express cholecystokinin (CCK-B) receptors and are able to process gastrin (G) as far as pro-G and G-gly (precursor forms) and this may be associated with tumour proliferation (18). Gut hormone receptors are overexpressed in human cancer and allow receptor-targeted tumour imaging and therapy. A novel promising receptor for these purposes is the secretin receptor. Secretin receptors are expressed in the human liver particularly the biliary tract and cholangiocarcinomas but not the hepatocytes or hepatocellular carcinomas (19). Hepatic failure is associated with increased pancreatic glucagon levels (true hyperglucagonaemia is suppressed by glucose) (20). Methionine enkephalin and other opioid peptides have been shown to be increased in both cirrhosis and acute liver disease (21). Furthermore, there is evidence that the central mechanism involved in the brain-liver interaction in the development of symptoms of hepatic encephalopathy (such as pruritus and fatigue) involves the opioid system (22). A class of endogenous opioids is upregulated in liver disease particular to cholestasis, which contribute to pruritus, hypotension and encephalopathy. Symptoms associated with cholestasis are reversed or ameliorated by opioid receptor antagonists. Opioid receptor antagonists have been reported to relieve multiple symptoms, except for pruritus, and improve liver function as demonstrated in experimental cholestasis (23).

7B2 was identified in 1982 by Seidah et al during the purification of the N-terminal glycol-segment of proopiomelanocortin (POMC) from pig anterior pituitaries (24). Later, the same investigators reported the purification of its human pituitary homologue (25). The two sequences differed by only one amino acid. 7B2 cDNA cloning from various species has demonstrated the high evolutionary conservation of the 7B2 molecule, suggesting that 7B2 may be biologically relevant. In particular, the overall residue identity is extremely high (90-96%) among mammals, relatively high (67-83%) between mammals and frogs or fish, and low (17-22%) between vertebrates and invertebrates (26,27). Initially, 7B2 was revealed to be located in the pituitary gonadotrophs (26,27) and to respond to exogenous LH-releasing hormone (LHRH) (26). 7B2 has also been demonstrated to be located in tissues that are primary neuronal (the brain and adrenal medulla) or endocrine (pituitary, thyroid and pancreas) tissues, or those that are known to carry a sub-population of neuroendocrine cells (gastrointestinal tract). The highest levels are detected in the anterior lobe of the pituitary, followed by the neurointermediate lobe, hypothalamus, adrenal medulla, thyroid gland and pancreas (27). In cell cultures (normal pituitary cells), the secretion of 7B2 appears to be unaffected by GHRH and CRH, but is increased by LHRH (26,27).

7B2 is detectable in human plasma. It is present at remarkably high levels in early childhood, which gradually decrease to adult levels by 20 years of age and slowly rise again with aging (28,29). The levels of 7B2 are elevated in pregnancy, from the second to the fourth trimester, but sharply decline soon after delivery and return to normal by 4-6 weeks post-partum (30). Initial studies of plasma 7B2 level increases in patients suffering from chronic kidney failure and liver cirrhosis (28,29,31) have suggested that these organs are involved in 7B2 clearance.

In the present study, the plasma 7B2 immunoactivity (7B2-IR) levels were measured in patients with liver disease, mainly cirrhosis of various aetiologies, in a further attempt to investigate the hepatic handling of this protein.

**Patients and methods**

**Patients.** The present study was also undertaken by Dr L. Meleagros (Endocrine Unit, Hammersmith Hospital, London, UK). In total, 18 patients with liver disease, who were under the care of Dr J. Calam (Department of Medicine, Hammersmith Hospital), were studied. The study was approved by the Ethics Committee of Hammersmith Hospital (RPMS, Imperial College London) and written informed consent was obtained by the patients. Of these patients, seven (three male and four female), aged 37-67 [54.6±13.5 (SD)] years and weighing 51-96 [69.5±17.8 (SD)] kg, suffered from liver cirrhosis of cryptogenic (n=2) or alcoholic (n=5) aetiology. The remaining 11 patients (four male and seven female), aged 22-76 [56.1±17.6 (SD)] years and weighing 50-100 [67.7±14.8 (SD)] kg, suffered from miscellaneous liver abnormalities.

The clinical diagnosis was confirmed in the majority of patients by the histological examination of a percutaneous liver biopsy or by appropriate radiological investigations (Table I). The total number of patients and the numbers with jaundice, ascites/oedema and hepatic encephalopathy are also shown in Table I.

The medication received by the patients was as follows (number of patients with cirrhosis vs. without cirrhosis): folic acid (6 vs. 0), ranitidine (5 vs. 0), prednisolone (1 vs.2), vitamin K (3 vs. 0), parentrovite (2 vs. 1), lactulose (4 vs. 0), diuretics (0 vs. 2), heparin (0 vs.1), cyclosporin A (1 vs. 0), salazopyrine (0 vs. 1), insulin (0 vs. 1), neomycin (1 vs. 0) and cyproheptadine (0 vs. 1). In addition three patients with and one without cirrhosis were on protein-restricted diets, and three cirrhotic patients were on salt-restricted diets. Peripheral venous blood samples were obtained between
Immunisation and preparation of antisera. A peptide fragment corresponding to residues 23-39 of the authentic 180 amino acid 7B2 molecule was custom synthesised (Cambridge Research Biochemicals, Cambridge, UK) and conjugated to bovine serum albumin (BSA; Sigma Chemical Co., Dorset, Poole, UK) by carbodiimide. The conjugated material was emulsified in complete Freund’s adjuvant for the primary immunisation and in incomplete adjuvant for the booster injections. Freund’s adjuvant was prepared by mixing 8.5 ml n-hexadecane (Koch-Light Laboratories Ltd.) with 1.5 ml Arlasel A (Sigma Chemical Co.) and was then completed by the addition of heat-killed mycobacteria (1 mg/ml).

Emulsified conjugate (2 ml) containing 80 pg conjugated peptide was administered to New Zealand white rabbits via 0.5 ml subcutaneous injections, one into each groin and axilla. At three months subsequent to the primary immunisation, booster injections were administered at two-monthly intervals. Each injection contained 40 µg conjugated 7B2 (23-39) in 2 ml incomplete Freund’s adjuvant (i.e. without mycobacteria). The rabbits were bled from the marginal ear vein seven to ten days after each booster injection. Blood was allowed to clot at room temperature and the serum was separated by centrifugation. Each harvested serum sample was then evaluated for its ability to bind 125I-7B2 (23-39). For this test, 20 µl undiluted serum was added to each assay tube (in duplicate) containing assay buffer and label to a total volume of 700 µl.

The antisera that exhibited >70% binding after 1 h of incubation at room temperature followed by charcoal/dextran separation were subsequently tested at three dilutions in order to determine the optimal working dilution. The antiserum used in these studies was labelled AG7 and used at a final dilution of 1/160,000, with an affinity constant of 1.9x10⁶ l/mol with respect to the synthetic fragment. The antibody was shown to cross-react by 33% with authentic porcine 7B2 on a molar basis. No cross-reactivities were observed with human insulin, proinsulin, glucagon, secretin, SRIH, human pancreatic polypeptide, ACTH, N-terminal of POMC, β-lipoprotein (LPH), β-endorphin, GH, arginine vasopressin (AVP), oxytocin, ovine corticotrophin releasing factor (oCRF) and vasoactive intestinal peptide (VIP).

Iodination procedure. The synthetic fragment 7B2 was used for the preparation of (125I-Tyr4)-7B2 (23-39) by the standard chloramine T method (33).

Standards. The standards were prepared gravimetrically using the synthetic 7B2 fragment. Aliquots (10 µl), each containing 2 pmol 7B2 (23-39), were lyophilised to 10⁻² torr and stored in vacuo at -20°C.

Assay conditions. All samples were assayed in duplicate in 2-ml polystyrene tubes (LKB, Luckham Ltd.). A total of 100 µl of the sample was added to each assay tube. Phosphate buffer (0.4 ml of 0.6 M, pH 7.4), containing 10 mM EDTA, 7.5 mM sodium azide and 150 mM BSA was used as the assay buffer. The label and antiserum were made up in the same buffer and 100 µl of each was added to each assay tube to give a final volume of 700 µl.

Separation. Subsequent to a five-day incubation at 4°C, the antibody-bound label was separated from the free label by adding 250 µl of a suspension containing 4 mg charcoal (Norit GSX; Hopkin and Williams) coated with 0.4 mg clinical grade dextran (Sigma Chemical Co.) to each tube. The tubes were centrifuged at 1600 x g for 20 min at 4°C and the supernatant was aspirated immediately.

Gamma counting. Following separation, the charcoal pellet and supernatant were counted in multi-well gamma counters.

Table I. Characteristics of patients with liver disease.

| Diagnosis                   | Total no. | His | Rad | Jaun | Asc/Oed | Enc |
|-----------------------------|-----------|-----|-----|------|---------|-----|
| Cirrhosis                   | 7         | 4   | 3   | 5    | 3       | 5   |
| Primary sclerosing cholangitis | 1       | 1   | 1   | 1    | 0       | 0   |
| Hepatic metastases          | 6         | 6   | 6   | 1    | 1       | 0   |
| Budd-Chiari syndrome        | 1         | 1   | 1   | 1    | 0       | 0   |
| Fatty liver                 | 1         | 1   | 1   | 1    | 0       | 0   |
| Amyloid disease             | 1         | 1   | 0   | 0    | 0       | 0   |
| Cholelithiasis              | 1         | 0   | 0   | 1    | 0       | 0   |

Clinical features of 18 patients with liver disease. The columns indicate the number of patients, i.e. total in each group; His, patients in whom the clinical diagnosis was confirmed histologically; Rad, patients in whom the clinical diagnosis was confirmed by radiological investigations; Jaun, patients with jaundice; Asc/Oed, patients with ascites and oedema; Enc, patients with hepatic encephalopathy.

08:00-09:00 hours with the patients in a seated position. All medication was withheld on the morning of the study. Samples were collected in heparinised tubes for the plasma 7B2-IR estimations and were processed as described. The plasma samples (100 µl aliquots) were assayed for 7B2-IR in duplicate. Plasma bilirubin, alkaline phosphatase, aspartate aminotransferase, albumin, prothrombin time, electrolytes, urea and creatinine were measured at the Chemical Pathology Laboratory of Hammersmith Hospital.

7B2 radioimmunoassay (RIA). A sensitive RIA for 7B2-IR was developed in our laboratory as described previously (32).
VENETIKOU et al.: 7B2 IN LIVER DISEASE

Since synthetic 7B2 (23-39) was used as a standard, the results are expressed as 7B2 immunoreactive equivalents (7B2-IE).

Chromatographic profiles. Samples containing 7B2-IE were subjected to gel permeation chromatography. A 1.4x90-cm column of Sephadex G-100 was used to separate the components present in the plasma.

Table II. Plasma biochemistry and coagulation status in patients with liver disease.

| Variable                        | Cirrhotic       | Non-cirrhotic  | P-value |
|---------------------------------|-----------------|----------------|---------|
| Bilirubin (2-14 µmol/l)         | 203.1±81.7      | 32.4±14.8      | <0.02   |
| Alkaline phosphatase (30-130 IU/l) | 270.9±64.3      | 477.8±125.3    | ns      |
| Aspartate aminotransferase (10-35 U/l) | 167.3±41.6      | 57.7±13.8      | <0.01   |
| Albumin (35-55 g/l)             | 30.3±3.1        | 38.2±1.7       | <0.05   |
| Prothrombin time (11-15 seconds) | 20.7±2.2        | 15.2±0.5       | <0.05   |
| Sodium (136-149 mmol/l)         | 135.6±2.8       | 138.4±0.8      | ns      |
| Potassium (3.8-5.2 mmol/l)      | 3.9±0.2         | 4.3±0.2        | ns      |
| Bicarbonate (24-30 mmol/l)      | 24.1±0.8        | 25.0±1.2       | ns      |
| Urea (2.5-6.5 mmol/l)           | 7.3±2.0         | 5.3±1.2        | ns      |
| Creatinine (55-125 pmol/l)      | 148.4±46.8      | 85.9±4.3       | ns      |

Liver function tests and plasma biochemistry in patients with cirrhotic (n=7) and non-cirrhotic (n=11) liver disease. Normal ranges and units are in brackets in the variable column. Results are expressed as the mean ± SEM with the range in brackets. P-value shows the significance of differences between the groups. ns, not significant.

Figure 1. 7B2 concentrations in patients with liver disease of various aetiologies compared with those observed in patients with liver disease due to metastatic tumours. *P<0.05 vs. A.

The column was eluted with a 0.06 M phosphate buffer (pH 7.4) containing 10 mM EDTA, 0.3% BSA and 0.2 M NaCl, at a flow rate of 3.2 ml/h at 4°C.

The column was pre-calibrated with dextran blue [molecular weight (MW), 2,000,000], horse heart cytochrome C (MW, 12,384) and a trace amount of NaI125. Dextran blue, cytochrome C and a trace amount of NaI125 were added to each sample as internal markers. The elution coefficient (Kav) for each immunoreactive peak was calculated according to the method used by Laurent and Killander (34). Gel permeation chromatography of porcine pituitary extracts showed a major peak (90% of total immunoreactivity), eluting prior to cytochrome C (32).

Statistical analysis. Statistical analyses were performed using two-tailed t-tests. P<0.05 was used to indicate a statistically significant difference.

Results

Patients. The results of the liver function tests and plasma biochemistry in the patients with and without cirrhosis are presented in Table II. Among the cirrhotic patients, significantly raised plasma bilirubin and aspartate aminotransferase levels, a prolonged prothrombin time and a reduced plasma albumin level provided evidence of hepatocellular damage and impaired liver function. Among the non-cirrhotic patients, the...
plasma bilirubin level was slightly raised, since 2 patients in this group (one with hepatic metastases and one with cholelithiasis) had common bile duct obstruction. This group had a higher, although not statistically significant, mean alkaline phosphatase level compared with the cirrhotic group, due to intrahepatic (two patients with primary sclerosing cholangitis and one with amyloid infiltration) or extra-hepatic (one patient with hepatic metastases and one with cholelithiasis) cholestasis. However, the aspartate aminotransferase level was only marginally increased, while the plasma albumin level and prothrombin time were within or just above the normal range. Therefore, there was only minimal hepatocellular damage and impairment of liver function in the non-cirrhotic group. The plasma creatinine level was higher in the cirrhotic group compared with the non-cirrhotic group, although the difference was not significant due to the high intra-group variation.

The mean plasma 7B2-IR concentration in liver disease was 99.44±15.9 pmol/l. In the patients with hepatocellular damage due to metastatic tumours [Ca bronchus, carcinoid (n=6)], the 7B2-IR concentrations were higher [185±36.9 pmol/l, (P<0.05)] compared with the overall subjects with liver damage (Fig. 1).

When the 11 patients with other causes of liver damage were screened separately, the mean plasma 7B2-IR concentration was 56.68±4.5 pmol/l.

**Chromatography.** Fig. 2 shows a representative 7B2 plasma chromatographic profile from the patients with liver damage.

**Discussion**

In the present study, it was observed that 7B2-IR levels were increased in liver disease. In the majority of the patients with hepatocellular damage, the 7B2-IR levels ranged between 1.5- and 3-fold of the normal range compared with the control subjects. These data are in accordance with previous studies that have demonstrated increased 7B2 plasma levels in patients with cirrhosis (28). Kobori (35) also reported increased 7B2-IR in the plasma of 13 patients with cirrhosis.

In the present study, it was also evident that in individual patients with liver disease due to metastatic tumours (Ca bronchus, metastatic carcinoid), 7B2-IR was increased by >3-5-fold compared with the normal range. This agrees with the results of Suzuki et al (36) who showed that 7B2-IR is mainly encountered in neoplastic conditions, particularly endocrine or other tumours of the gastrointestinal tract. It is therefore difficult to conclude whether 7B2 is produced by the damaged hepatocyte or if it is released by the tumour itself, particularly for patients with liver damage due to metastatic tumours. The immunocytochemical analysis of tumour tissues has revealed more extensive associations between 7B2 and neuroendocrine tumours than the titration of its circulating levels. 7B2 has been detected in the majority of benign, and approximately half of malignant, pancreatic tumours, particularly insulin-producing tumours (36-39). Notably, insulinomas containing only proinsulin and not the active mature form were shown to also lack 7B2 (38). 7B2-IR has been detected in bronchial carcinoids and small-cell lung carcinomas that are associated with liver metastases (36-39).

Various other neuropeptides have been investigated in liver diseases and alterations in their levels have been observed. Neutrotransin (NT) is expressed in the human fetal liver, but not in adults. NT is also expressed in fibroblasticoma, although it is not expressed in the regenerating rat liver (42). NT has also been shown to be produced by a fibroblasticoma hepatoma (14). The majority of liver tumours express cholecystokinin (CCK-B) receptors and are able to process gastrin (G) as far as pro-G and G-gly (the precursor forms), which may be associated with tumour proliferation (43,44). Gut hormone receptors are overexpressed in human cancer and allow receptor-targeted tumour imaging and therapy. A novel promising receptor for these purposes is the secretin receptor. Secretin receptors are expressed in the human liver, particularly in the biliary tract and cholangiocarcinomas, but not in hepatocytes or hepatocellular carcinomas (19). Hepatic failure is associated with increased pancreatic glucagon levels (true hyperglucagonaemia suppressed by glucose) (20). Methionine-enkephalin and other opioid peptides have been shown to be increased in cirrhosis and acute liver disease (23). Additionally, there is evidence that the central mechanism involved in the brain-liver interaction in the development of the symptoms of hepatic encephalopathy (such as pruritus and fatigue) involves the opioid system (23,44). A class of endogenous opioids is upregulated in liver disease, particularly cholestasis, which contribute to pruritus, hypotension and encephalopathy. Symptoms associated with cholestasis are reversed or at least ameliorated by mu-opioid receptor antagonists. Opioid receptor antagonists have been reported to relieve multiple symptoms, with the exception of pruritus, and improve liver function, as demonstrated in experimental cholestasis (23,44). In a multiple primary hepatic carcinoid tumour of the liver, neuron-specific enolase (NSE) and chromogranin were identified immunocytochemically in all tumour cell types. The S-100 protein, human choriogonadotrophin and serotonin were also observed (45). It has been suggested previously that 7B2-IR is co-localised with several chromogranins in the secretory granules (44,45) and that it belongs to the granin family (46). It is therefore possible that, in patients whose disease is due to primary or secondary liver neoplasms, 7B2-IR levels may be even higher than in cirrhosis of other aetiologies, due to the overproduction of 7B2 by the tumour cells, as observed in several liver neoplasms that have been positively stained for chromogranin peptides (47,48).
In neuroendocrine cells, 7B2 functions as a specific chaperone for proprotein convertase 2 (proPC2) (49). It has been proposed that 7B2 serves as an intracellular proPC2 chaperone and prevents the premature activation of the zymogen during its transit in the regulated secretory pathway. It appears that pro7B2 attaches to proPC2 in the endoplasmic reticulum (ER). This attachment is facilitated by the relatively alkaline conditions of this compartment. The inactive complex is transported to the trans-Golgi network (TGN) where pro7B2 is cleaved into an N-terminal protein and a C-terminal peptide. ProPC2 is then autokatlytically cleaved after the prodomain as the complex is transported into secretory granules. In these organelles, the prodomain and 7B2 fragments dissociate from the enzyme, which then becomes fully activated. Thus, 7B2 regulates PC2 activation (49). The 7B2 and PC2 proteins are packaged into secretory granules. It is unclear whether proPC2 requires an association with 7B2 polypeptides in order to be sorted into these organelles. Although not yet established, 7B2 may be a component of the PC2 aggregates that are sorted into the secretory granules (50,51).

Since 7B2 has been grouped with the chromogranins and secretogranins into the so-called granin family of proteins, one of its presumed functions is to facilitate the sorting of neuroendocrine proteins from the secretory granules (46). By studying POMC-expressing non-pituitary tumours, corticotrophin-like-intermediate lobe peptide (CLIP), a product of corticotrophin cleavage by PC2, was detected only in the tumours that expressed PC2 (39,51), and it may be assumed that these tumours also contain 7B2. 7B2 has also been detected in pituitary tumours (52,53). It is also noteworthy that, unlike PC2-null mice which are viable, 7B2-null mutants die early in life from Cushing's disease due to ACTH hypersecretion by the intermediate lobe, suggesting the possible involvement of 7B2 in secretory granule formation and secretion regulation (54). The 7B2-null mice with Cushing's disease may be saved early in life by an adrenalectomy (55). Neither our plasma ACTH tumours of Cushing's patients (26,56), nor those studied by Natori et al (57,58) allow the conclusion that 7B2-IR levels in plasma are increased in Cushing's patients, and corticotrophic adenomas have not shown increased 7B2 secretion in vitro, although 7B2 is concomitantly secreted with ACTH by AtT-20 tumourous cells in vitro (56). It has been suggested that the lethal phenotype that is exhibited by 7B2-null mice with a complex Cushing's disease-like pathology, is due to intermediate lobe ACTH hypersecretion as a consequence of the interruption of PC2-mediated peptide processing, as well as undefined consequences of the loss of 7B2.

Sarac et al (59) reported that 7B2-null mice exhibit a multisystem disorder that includes severe pathoanatomical and histopathological alterations to vital organs, including the heart and spleen, but most notably the liver, in which massive steatosis and necrosis are observed. Metabolic derangements in the glucose metabolism result in glycoegen and fat deposition in the liver under conditions of chronic hypoglycaemia. Liver failure is also likely to contribute to abnormalities in blood coagulation and blood chemistry, such as lactate acidosis. It has been suggested that a hypoglycaemic crisis coupled with respiratory distress and intensive internal thrombosis is likely to result in the rapid deterioration and death of the 7B2-null mice (59).

All the aforementioned observations and knowledge make 7B2 an intriguing molecule, whose definite function remains to be elucidated in view of the fact that it appears to exist in cells where PC2 activity is not evident (60), thus suggesting a bigger biological role for 7B2 compared with PC2.

The family of proprotein convertases has been implicated in tumourigenesis and metastasis in animal models. In a study assessing PC1, PC2 and 7B2 in primary colon cancers, PC1 and PC2 mRNA, protein expression and protein cleavage profiles were observed to be altered in liver colorectal metastases compared with unaffected and normal livers. Active PC1 protein was overexpressed in tumours, which correlated with its mRNA profile. Moreover, the enhanced PC2 processing pattern in the tumours was correlated with the overexpression of its specific binding protein 7B2. These results were corroborated by immunocytochemistry. The authors suggested that the exclusive presence of 7B2 in metastatic tumours may represent a new target for early diagnosis, prognosis and/or treatment (61).

Liver dysfunction may be due to various pathologies and drug interactions, and all the aforementioned observations suggest that 7B2 may be have a more biologically important role than PC2. The biological role of 7B2 appears to be important for animal survival, and more studies should be undertaken to identify a definite role for this protein, not only in liver disease, but also in other clinical entities.

References

1. Scheuer A, Grün R and Lehman FG: Peptide hormones in liver cirrhosis and hepatocellular carcinoma. Oncodev Biol Med 2: 1-10, 1981.
2. Parkes DG, Yamamoto GY, Vaughan JM and Vale WW: Characterization and regulation of corticotrophin-releasing factor in the human hepatoma NPLC-ΚC cell line. Neuroendocrinology 57: 663-669, 1993.
3. Nawata H, Higuchi K, Kiyama S, Kato K, Ibayashi H, Mimura K, Sueshi K, Zingami H and Imura H: Corticotrophin-releasing hormone- and adrenocorticotropic-producing pituitary carcinoma with metastases to the liver and lung in a patient with Cushing's disease. J Clin Endocrinol Metab 71: 1068-1073, 1990.
4. Mowat NA, Edwards CR, Fischer R, McNeilly AS, Green JR and Dawson AM: Hypothalamic-pituitary-gonadal function in men with cirrhosis of the liver. Gut 17: 345-350, 1976.
5. Van Thiel DH, Lester R and Vaitukaitis J: Evidence for a defect in pituitary secretion of luteinizing hormone in chronic alcoholic men. J Clin Endocrinol Metab 47: 499-507, 1978.
6. Wang YJ, Wu JC, Lee SD, Tsai YT and Lo KJ: Gonadal dysfunction and changes in sex hormones in postnecrotic cirrhotic men: a matched study with alcoholic men. Hepatogastroenterology 38: 531-534, 1991.
7. Bell H, Raknerud N, Falch JA and Haug E: Inappropriately low levels of gonadotrophins in amnorrhoeic women with alcoholic and non-alcoholic cirrhosis. Eur J Endocrinol 132: 444-449, 1995.
8. Zietz B, Lock G, Plach B, Drobnik W, Grossmann J, Schölmerich J and Straub RH: Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis. Eur J Gastroenterol Hepatol 15: 495-501, 2003.
9. Zhang J, Huang G and Huang W: Gonadotropin releasing hormone and its receptor in the tissue of human hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 78: 343-346, 1998 (In Chinese).
10. Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I and Hadziyannis SJ: Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 21: 1535-1542, 1995.
11. Eaves RI, Ben-Yehuda A and Lorberbour-Galvis H: Surface antigens/receptors for targeted cancer treatments: the GnRH receptor/binding site for targeted adenocarcinoma therapy. Curr Cancer Drug Targets 4: 673-687, 2004.
12. Ataseven H, Bahcecioglu IH, Kuzu N, et al: The levels of grelin, leptin, TNF-α, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HDV infection. Mediators Inflamm 2006: 154293.

13. Berasain C, Castillo J, Perugorría MJ, Prieto J and Avila MA: Amphiregulin: a new growth factor in hepatocarcinogenesis. Cancer Lett 254: 30-41, 2007.

14. Ehrenfried JA, Zhou Z, Thompson JC and Evers BM: Expression of the neurotensin gene in fetal liver human and fibrolamellar hepatocellular carcinoma. J Pediatr 129: 484-489, 1996 (In Japanese).

15. Xidakis C, Mastromodou N, Notas G, Renieri E, Kolios G, Kouroulou M and Thermos K: RT-PCR and immunocytochemistry studies support the presence of somatostatin, cortistatin and somatostatin receptor subtypes in rat Kupffer cells. Hepatology 37: 76-82, 2003.

16. Raderer M, Hejna M, Muller C, Kornek G, Kurtaran A, Virgolini I, Fiebiger W, Hamilton G and Scheuhaier W: Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 16: 197-1201, 2000.

17. Katsumata N, Chakraborty C, Myal Y, Schroeder ICT, Murphy LJ, Shiu RP and Friesen HG: Molecular cloning and expression of peptide 23, a growth hormone-releasing hormone-inducible pituitary protein. Endocrinology 136: 1332-1339, 1995.

18. Caplin M, Khan K, Savage K, Rode J, Varro A, Michaeli D, Grineski M, Gwandal R and Nandi S: Isolation and processing of gastrin in hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma. J Hepatol 30: 519-526, 1999.

19. Körner M, Hayes GM, Rehmann R, Zimmermann A, Scolz A, Wiedemann B, Miller LJ and Reubi JC: Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma. J Hepatol 45: 825-835, 2006.

20. Christofides ND: Pancreatic glucagon. In: Radioimmunoassay of Gut Regulatory Peptides. Bloom SR and Long GL (eds). WB Saunders Company Ltd., p34, 1982.

21. Thorton JR and Losowsky MS: Methionine enkephalin is increased in plasma in acute liver disease and is present in bile and urine. J Hepatol 8: 53-59, 1989.

22. Yudaydin C: The central opioid system in liver disease and its complications. Metab Brain Dis 16: 79-83, 2001.

23. Davis M: Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics. Clin Pharmacokinet 46: 825-850, 2007.

24. Hsi KL, Seidah NG, De Serres G and Chretien M: Isolation and NH2-terminal sequence of a novel porcine anterior pituitary polypeptide transforming protein TVFV60. FEBS Lett 147: 261-266, 1982.

25. Takumi I, Steiner DF, Takumi T and Bertagna X: Expression of the neuroendocrine cell marker 7B2 in human ACTH secreting tumours. Clin Endocrinol (Oxf) 36: 597-603, 1992.

26. Ito H, Masuda H, Tahara E and Wittekind C: Carcinoid tumour of the liver. Disch Med Wochenschr 114: 623-627, 1989 (In German).

27. Marzioni M, Fava G and Benedetti A: Nervous and neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. World J Gastroenterol 12: 3471-3480, 2006.

28. Virgolini I, Fiebiger W, Hamilton G and Schulten W: The levels of grelin, neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary gland and pituitary adenomas: analysis by immunocytochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas. Arch Pathol Lab Med 132: 1225-1232, 1998.

29. Roebroek AJ, Martens GJ, Duits AJ, Schalken JA, van Bokhoven A, Wagenaar SS and van de Ven WJ: Differential expression of the gene encoding the novel pituitary polypeptide 7B2 in human lung cancer cells. Cancer Res 49: 4154-4158, 1989.

30. Kapsoucki M, Shultes A, Read D and Hardy KJ: Expression of neurotensin in endocrine tumors. J Clin Endocrinol Metab 70: 100-106, 1990.

31. Shennan KI, Chretien M and Marcinkiewicz M: Ultrastructural localization of secretory granule constituent chromogranin B and 7B2. Pathol Res Pract 183: 617-619, 1988.

32. Ozawa H and Takada K: The granin family - its role in sorting and secretory granule formation. Cell Struct Funct 20: 415-420, 1995.

33. Qin LX and Tang ZY: The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 8: 385-392, 2002.

34. Geller SA, Dhall D and Alsabeh R: Application of immunocytochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas. Arch Pathol Lab Med 132: 490-499, 2008.

35. Braks JA and Mariens GJ: 7B2 is a neuroendocrine chaperone that transiently interacts with prohormone convertase PC2 in the secretory pathway. Cell 78: 263-273, 1999.

36. Shennan KI, Taylor NA and Docherty K: Calcium- and pH-dependent aggregation and membrane association of the precursor of the prohormone convertase PC2. J Biol Chem 269: 18646-18650, 1994.

37. Jorg G, Taylor NA, Scougall KT, Docherty K and Shennan KI: The propeptide of the prohormone convertase PC2 acts as a transferable aggregation and membrane-association signal. Eur J Biochem 257: 41-46, 1998.

38. Lloyd RV, Lin L, Qian X, Scheithauer BW, Young WF Jr and Davis DH: Analysis of the chromogranin A post-translational cleavage product pancreastatin and the prohormone convertase PC2 and PC3 in normal and neoplastic human pituitarys. Am J Pathol 146: 1188-1198, 1995.

39. Takami I, Steiner DF, Sano N, Teramoto A and Osamura RY: Localization of prohormone convertases 1/3 and 2 in the human pituitary gland and pituitary adenomas by immunocytochemistry, immunoelectron microscopy, and laser scanning microscopy. Mod Pathol 11: 232-238, 1998.

40. Westphal CH, Muller L, Zhou A, Zhu X, Bonner-Weir S, Schambelan M, Steiner DF, Lindberg I and Leder P: The neuroendocrine receptor 7B2 in rat, human and mouse. J Biol Chem 269: 139-143, 1985.

33. Hunter WH and Greenwood FC: Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 194: 495-496, 1962.

41. Lauret TC and Killilea DW: A theory of gel filtration and its experimental verification. J Chromatogr A 134: 317-330, 1964.

34. Kobori H: Immunoreactive 7B2 concentrations in plasma and cerebrospinal fluid in physiological conditions and the responses to oral glucose load, intravenous LHRH, TRH and arginine infusion. Nihon Naibunpi Gakkai Zasshi 65: 1135-1148, 1989 (In Japanese).

35. Suzuki H, Ghaetie MA, Williams SJ, Uttenhall LO, Facer P, Bishop AE, Polak JM and Bloom SR: Production of pituitary protein 7B2 immunoreactivity by endocrine tumours and its possible diagnostic value. J Clin Endocrinol Metab 63: 758-765, 1987.

36. Suzuki H, Christofides ND, Chretien M, Seidah NG, Polak JM and Bloom SR: Developmental changes in immunoreactive content of novel pituitary protein 7B2 in human pancreas and its identification in pancreatic tumours. Diabetes 36: 1276-1279, 1987.

37. Azzeni C, Yu YJ, Baggi MT, D’Adda T, Timson C, Polak JM and Bordi C: Studies on co-localization of 7B2 and pancreatic hormones in normal and tumoural islet cells. Virchows Arch A Pathol Anat Histopathol 421: 457-466, 1992.

38. Vieu D, Linard CG, Mbikay M, Lenne F, Chretien M, Laton JP and Bertagna X: Expression of the neuroendocrine cell marker 7B2 in human ACTH secreting tumours. Clin Endocrinol (Oxf) 36: 597-603, 1992.

39. Iguchi H, Hara N, Hayashi I, Ohta M, Bloom SR and Chretien M: Elevation of a novel pituitary protein (7B2) in the plasma in small cell carcinoma of the lung. Eur J Cancer Clin Oncol 25: 1225-1232, 1989.

40. Roebroek AJ, Martens GJ, Duits AJ, Schalken JA, van Bokhoven A, Wagenaar SS and van de Ven WJ: Differential expression of the gene encoding the novel pituitary polypeptide 7B2 in human lung cancer cells. Cancer Res 49: 4154-4158, 1989.

41. Kapsoucki M, Shultes A, Read D and Hardy KJ: Expression of neurotensin in endocrine tumors. J Clin Endocrinol Metab 70: 100-106, 1990.
55. Laurent V, Kimble A, Peng B, Zhu P, Pintar JE, Steiner DF and Lindberg I: Mortality in 7B2 null mice can be rescued by adrenalectomy. Involvement of dopamine in ACTH hypersecretion. Proc Natl Acad Sci USA 99: 3087-3092, 2002.

56. Venetikou MS, Burrin JM, Ghatei MA and Bloom SR: ACTH and 7B2 release by atT-20 cells in vitro: effect of CRF, VIP, AVP and SRIF during perifusion and static culture. FEBS J 275 (Suppl): 262, 2008.

57. Natori S, Iguchi H, Nawata H, Kato K, Ibayashi H, Nagasaki H and Chrétien M: Evidence for the release of a novel pituitary polypeptide (7B2) from the growth hormone-producing pituitary adenoma of patients with acromegaly. J Clin Endocrinol Metab 66: 430-437, 1988.

58. Natori S, Iguchi H, Ohashi M, Nakao R, Bloom SR and Nawata H: Effect of octapeptide analogue (SMS 201-995) on plasma 7B2 (a neuroendocrine polypeptide) levels in patients with acromegaly. Clin Endocrinol (Oxf) 32: 49-55, 1990.

59. Sarac MS, Zieske AW and Lindberg I: The lethal form of Cushing's in 7B2 null mice is induced by multiple metabolic and hormonal abnormalities. Endocrinology 143: 2324-2332, 2002.

60. Seidel B, Dong W, Savaria D, Zheng M, Pintar JE and Day R: Neuroendocrine protein 7B2 is essential for proteolytic conversion and activation of proprotein convertase 2 in vivo. DNA Cell Biol 17: 1017-1029, 1998.

61. Tzimas GN, Chevet E, Jenna S, Nguyên DT, Khatib AM, Marcus V, Zhang Y, Chrétien M, Seidah NG and Metrakos P: Abnormal expression and processing of the proprotein convertase PC1 and PC2 in human colorectal liver metastases. BMC Cancer 17: 149, 2005.